Drug research

Ruxolitinib

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as JAKAFI; Jakafi

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389	KPTI	Phase 3	Active not recruiting	2026-02-20Actual
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806	KPTI	Phase 2	Recruiting	2027-06Estimated
Actuate 1901: 9-ING-41 in MyelofibrosisNCT04218071	ACTU	Phase 2	Completed	2022-10-13Actual

KPTIActive not recruitingPrimary completion: 2026-02-20 · Actual

Trial details

KPTIRecruitingPrimary completion: 2027-06 · Estimated

Trial details

ACTUCompletedPrimary completion: 2022-10-13 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.